Technology ID

Rabies Vaccine for the Oral Immunization of Domesticated Animals, Wildlife and Feral Animals

Linked ID
Bernhard Dietzschold (Thomas Jefferson University)
Charles Rupprecht (CDC)
D. Craig Hooper (Thomas Jefferson University)
Matthias Schnell (Thomas Jefferson University)
Lead Inventors
Bernhard Dietzschold (Thomas Jefferson University)
Charles Rupprecht (CDC)
D. Craig Hooper (Thomas Jefferson University)
Matthias Schnell (Thomas Jefferson University)
Development Stages
Pre-clinical (in vivo)
Development Status
  • In vitro data available
  • In vivo data available (animal)
Therapeutic Areas
Infectious Disease
Commercial Applications
  • Wildlife and humane shelter rabies prevention and control programs
  • Improved rabies vaccines for pets and livestock
  • Humane, targeted approach to elimination of rabies reservoirs in feral animal populations
This invention, developed by the CDC and collaborators, entails a live, attenuated recombinant rabies virus vaccine that can elicit an effective anti-rabies immune response in animal recipients. Inoculation with a live, attenuated, rabies virus allows for the optimized production of immunity in the absence of pathogenicity. Oral administration of rabies vaccines is often a preferred route of vaccine delivery because it is most effective in wildlife. Unfortunately, availability of an oral vaccine for canines has been a significant hurdle to date.

This vaccine technology could be used for immunization of stray dogs by an oral route. In developing nations, more than 90% of human exposure events and 99% of human deaths due to rabies are caused by rabid dogs. Using this vaccine with a broadly implemented oral vaccination strategy provides a promising opportunity for reducing transmission of rabies between stray dogs and, thereby, increasing protection for people.
Competitive Advantages
  • Safe and effective
  • Oral immunization is the most practical and efficient method of rabies vaccination of wildlife and feral animals
  • Vaccine has demonstrated protection in vivo
  • Recombinant, non-neuroinvasive virus expressing a neuroinvasive glycoprotein and/or pro-apoptotis gene safely induces a robust and desirable immunological response

Request More Info

Licensing Contact